| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $10,051 | 1 | 100 |
Sells | $0 | 0 | 0 |
| Grossman William | Interim Chief Medical Officer | 1 | $10,051 | 0 | $0 | $10,051 |
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after …
Over the last 12 months, insiders at enGene Holdings Inc. have bought $10,051 and sold $0 worth of enGene Holdings Inc. stock.
On average, over the past 5 years, insiders at enGene Holdings Inc. have bought $4.04M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Grossman William (Interim Chief Medical Officer) — $10,051.
The last purchase of 5,102 shares for transaction amount of $10,051 was made by Grossman William (Interim Chief Medical Officer) on 2026‑09‑22.
| 2026-09-22 | Grossman William | Interim Chief Medical Officer | 5,102 0.0079% | $1.97 | $10,051 | -17.80% | ||
| 2024-10-30 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10 percent owner | 561,797 1.1339% | $8.90 | $5M | -38.08% | ||
| 2024-10-08 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10 percent owner | 800 0.0012% | $6.60 | $5,278 | -24.30% | ||
| 2024-10-07 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10 percent owner | 11,844 0.0176% | $6.55 | $77,531 | -19.66% | ||
| 2024-10-04 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10 percent owner | 5,997 0.0089% | $6.54 | $39,242 | -19.31% | ||
| 2024-10-03 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10 percent owner | 5,769 0.0085% | $6.48 | $37,397 | -17.31% | ||
| 2024-10-02 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10 percent owner | 10,153 0.0147% | $6.37 | $64,697 | -16.80% | ||
| 2024-10-01 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10 percent owner | 35,279 0.0515% | $6.44 | $227,158 | -17.43% | ||
| 2024-09-30 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10 percent owner | 341,332 0.4906% | $6.34 | $2.16M | -18.56% | ||
| 2024-09-27 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10 percent owner | 41,639 0.0564% | $5.97 | $248,699 | -11.57% | ||
| 2024-09-27 | Cooper Ronald Harold Wilfred | Chief Executive Officer | 10,000 0.0129% | $5.70 | $57,000 | -11.57% | ||
| 2023-12-29 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10 percent owner | 10,020 0.0206% | $9.06 | $90,771 | -6.28% | ||
| 2023-12-28 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10 percent owner | 5,050 0.0088% | $7.69 | $38,827 | +6.66% | ||
| 2023-12-27 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10 percent owner | 2,750 0.0045% | $7.17 | $19,711 | +17.85% |
| Grossman William | Interim Chief Medical Officer | 5102 0.0076% | $8,265.24 | 1 | 0 | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | 10 percent owner | 3032430 4.5249% | $4.91M | 12 | 0 | <0.0001% |
| Cooper Ronald Harold Wilfred | Chief Executive Officer | 10000 0.0149% | $16,200.00 | 1 | 0 | <0.0001% |
$5,552,811 | 165 | 5.84% | $106.2M | |
$16,280,851 | 76 | 1.48% | $118.27M | |
$4,898,715 | 46 | 40.75% | $114.69M | |
$130,095 | 43 | 45.19% | $111.24M | |
$63,049,419 | 31 | 2.87% | $107.27M |
| Increased Positions | 43 | +122.86% | 26M | +62.76% |
| Decreased Positions | 14 | -40% | 8M | -19.09% |
| New Positions | 26 | New | 12M | New |
| Sold Out Positions | 6 | Sold Out | 3M | Sold Out |
| Total Postitions | 64 | +82.86% | 59M | +43.66% |
| Fcpm Iii Services B.V. | $85,248.00 | 14.38% | 9.63M | 0 | 0% | 2025-09-30 |
| Vr Adviser, Llc | $44,661.00 | 7.53% | 5.05M | 0 | 0% | 2025-09-30 |
| Kynam Capital Management, Lp | $44,198.00 | 7.45% | 4.99M | 0 | 0% | 2025-09-30 |
| Blue Owl Capital Holdings Lp | $29,011.00 | 4.89% | 3.28M | -450,000 | -12.07% | 2025-09-30 |
| Cormorant Asset Management, Lp | $20,564.00 | 3.47% | 2.32M | 0 | 0% | 2025-09-30 |
| Braidwell Lp | $20,057.00 | 3.38% | 2.27M | +2M | New | 2025-09-30 |
| Deep Track Capital, Lp | $19,818.00 | 3.34% | 2.24M | -2M | -50.87% | 2025-09-30 |
| Perceptive Advisors Llc | $18,561.00 | 3.13% | 2.1M | +2M | New | 2025-09-30 |
| Point72 Asset Management, L.P. | $10,694.00 | 1.8% | 1.21M | +100 | +<0.01% | 2025-09-30 |
| Frazier Life Sciences Management, L.P. | $10,243.00 | 1.73% | 1.16M | +1M | New | 2025-09-30 |